MICHAEL S PERRY Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for MICHAEL S PERRY.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of MICHAEL S PERRY. MICHAEL S PERRY is a Director in AmpliPhi Biosciences Corp ($APHB) and a Director in ARROWHEAD PHARMACEUTICALS, INC. ($ARWR) and an Chief Executive Officer in Avita Therapeutics, Inc. ($RCEL).
Address: 1155 MERRILL STREET, #302 MENLO PARK 94025 CA
Companies in which MICHAEL S PERRY is an Insider
Armata Pharmaceuticals, Inc.
Industry: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
Position of MICHAEL S PERRY: Director
Holdings: 124,270 shares
Current Value: $67,106
Latest Transaction: May 24 2019
$APHB Market Capitalization: $5.61M
$APHB Previous Close: $0.54
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD View transactions
ARROWHEAD PHARMACEUTICALS, INC.
Industry: PHARMACEUTICAL PREPARATIONS [2834]
Position of MICHAEL S PERRY: Director
Holdings: 15,000 shares
Current Value: $29,400
Latest Transaction: May 18 2020
$ARWR Market Capitalization: $149.83M
$ARWR Previous Close: $1.96
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD View transactions
AVITA Medical, Inc.
Industry: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
Position of MICHAEL S PERRY: Chief Executive Officer
Holdings: 472,948 shares
Latest Transaction: Sep 16 2020
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD View transactions
Latest Insider Trading Transactions of MICHAEL S PERRY
Sentiment: All, APHB, ARWR, RCEL
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sep 16 2020 | RCEL | Avita Therapeutics ... | PERRY MICHAEL S | Chief Executive Off ... | Sell | S | 27.41 | 9,000 | 246,690 | 425,087 | 434.1 K to 425.1 K (-2.07 %) |
| Sep 16 2020 | RCEL | Avita Therapeutics ... | PERRY MICHAEL S | Chief Executive Off ... | Sell | S | 27.23 | 23,769 | 647,230 | 434,087 | 457.9 K to 434.1 K (-5.19 %) |
| Sep 16 2020 | RCEL | Avita Therapeutics ... | PERRY MICHAEL S | Chief Executive Off ... | Sell | S | 26.99 | 15,092 | 407,333 | 457,856 | 472.9 K to 457.9 K (-3.19 %) |
| Sep 16 2020 | RCEL | Avita Therapeutics ... | PERRY MICHAEL S | Chief Executive Off ... | Grant | A | 0.00 | 68,504 | 0 | 472,948 | 404.4 K to 472.9 K (+16.94 %) |
| Sep 11 2020 | RCEL | Avita Therapeutics ... | PERRY MICHAEL S | Chief Executive Off ... | Option Exercise | A | 5.99 | 25,000 | 149,750 | 150,000 | |
| Sep 11 2020 | RCEL | Avita Therapeutics ... | PERRY MICHAEL S | Chief Executive Off ... | Sell | S | 26.02 | 20,000 | 520,400 | 404,444 | 424.4 K to 404.4 K (-4.71 %) |
| Sep 11 2020 | RCEL | Avita Therapeutics ... | PERRY MICHAEL S | Chief Executive Off ... | Sell | S | 26.26 | 7,128 | 187,181 | 424,444 | 431.6 K to 424.4 K (-1.65 %) |